<li id="4w4yg"></li>
<button id="4w4yg"><input id="4w4yg"></input></button>
<li id="4w4yg"></li>
  • <li id="4w4yg"><source id="4w4yg"></source></li>
  • <strike id="4w4yg"></strike>
    <strike id="4w4yg"><acronym id="4w4yg"></acronym></strike><button id="4w4yg"><dl id="4w4yg"></dl></button>
    <strike id="4w4yg"><acronym id="4w4yg"></acronym></strike>
    <bdo id="4w4yg"></bdo>
    產(chǎn)品展示 / products 您的位置:網(wǎng)站首頁 > 產(chǎn)品展示 > 細(xì)胞庫 > 細(xì)胞系 > 人甲狀腺癌乳頭狀細(xì)胞BCPAP
    人甲狀腺癌乳頭狀細(xì)胞BCPAP

    人甲狀腺癌乳頭狀細(xì)胞BCPAP

    簡要描述:青旗(上海)生物技術(shù)發(fā)展有限公司,總部位于上海浦東新區(qū),依托本地高校資源,逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺,在標(biāo)準(zhǔn)化細(xì)胞庫建立及細(xì)胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營原代細(xì)胞、細(xì)胞系、ELISA試劑盒、感受態(tài)細(xì)胞和HPLC檢測等科研產(chǎn)品與服務(wù)。我們秉承對用戶負(fù)責(zé)的態(tài)度,以對科研的高度嚴(yán)謹(jǐn),以嚴(yán)格的質(zhì)量控制,為廣大生物醫(yī)學(xué)科研用戶提供更優(yōu)質(zhì)的服務(wù)!

    更新時(shí)間:2021-05-25

    廠商性質(zhì):生產(chǎn)廠家

    瀏覽次數(shù):482

    詳情介紹
    品牌其他品牌貨號BFN60810525
    規(guī)格T25培養(yǎng)瓶x1 1.5ml凍存管x2供貨周期現(xiàn)貨
    主要用途僅供科研應(yīng)用領(lǐng)域醫(yī)療衛(wèi)生,生物產(chǎn)業(yè)

    細(xì)胞名稱

    人甲狀腺癌乳頭狀細(xì)BCPAP

    img1

    貨物編碼

    BFN60810525

    產(chǎn)品規(guī)格

    T25培養(yǎng)x1

    1.5ml凍存x2

    細(xì)胞數(shù)量

    1x10^6

    1x10^6

    保存溫度

    37

    -198

    運(yùn)輸方式

    常溫保溫運(yùn)輸

    干冰運(yùn)輸

    安全等級

    1

    用途限制

    僅供科   3

     

    培養(yǎng)體系

    DMEM高糖(不含丙酮酸鈉+10%FBS+1%三抗

    培養(yǎng)溫度

    37

    二氧化碳濃度

    5%

    簡介

    人甲狀腺癌乳頭狀細(xì)BCPAP76歲女性供體,該細(xì)胞源DMSZ

    注釋

    Part of: Cancer Cell Line Encyclopedia (CCLE) project.

    Part of: COSMIC cell lines project.

    Part of: TCGA-110-CL cell line panel.

    Doubling time: ~30 hours (DSMZ).

    Microsatellite instability: Stable (MSS) (Sanger).

    Omics: Deep exome analysis.

    Omics: Deep RNAseq analysis.

    Omics: DNA methylation analysis.

    Omics: SNP array analysis.

    Omics: Transcriptome analysis.

    Caution: Was originally classified a thyroid gland papillary carcinoma (PTC) but is now considered to be a poorly differentiated thyroid gland carcinoma (PDTC) (PubMed=23162534).

    基因突變

    Homozygous for BRAF p.Val600Glu (c.1799T>A) (ClinVar=VCV000013961) (PubMed=23162534; PubMed=23833040; PubMed=30737244).

    Heterozygous for TERT c.228C>T (-124C>T); in promoter (PubMed=23833040; PubMed=30737244).

    Homozygous for TP53 p.Asp259Tyr (c.775G>T) (PubMed=14522906; PubMed=23162534; PubMed=30737244).

    HLA信息

    /

    STR信息

    Amelogenin        X

    CSF1PO        13

    D2S1338        18

    D3S1358        16,17

    D5S818        10,11

    D7S820        10

    D8S1179        12,13

    D13S317        12

    D16S539        11,12

    D18S51        13,17

    D19S433        13.2,15

    D21S11        30,31.2

    FGA        20,23

    Penta D        10,11

    Penta E        5,12,17

    TH01        6,9.3

    TPOX        8,11

    vWA        14,17

    參考文獻(xiàn)

    PubMed=17725429; DOI=10.1089/thy.2007.0097

    Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V., Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R., Trovisco V., Cirnes L., Alves C., Velho S., Soares P., Sobrinho-Simoes M.

    Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.

    Thyroid 17:707-715(2007)

     

    PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026

    van Staveren W.C.G., Solis D.W., Delys L., Duprez L., Andry G., Franc B., Thomas G., Libert F., Dumont J.E., Detours V., Maenhaut C.

    Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype.

    Cancer Res. 67:8113-8120(2007)

     

    PubMed=18713817; DOI=10.1210/jc.2008-1102

    Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R.

    Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

    J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

     

    PubMed=19087340; DOI=10.1186/1471-2407-8-371

    Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.

    Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples.

    BMC Cancer 8:371-371(2008)

     

    PubMed=20164919; DOI=10.1038/nature08768

    Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

    Signatures of mutation and selection in the cancer genome.

    Nature 463:893-898(2010)

     

    PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690

    Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.

    Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.

    Clin. Cancer Res. 17:7248-7264(2011)

     

    PubMed=22087789; DOI=10.1186/1755-8166-4-26

    Maric I., Viaggi S., Caria P., Frau D.V., Degan P., Vanni R.

    Centrosomal and mitotic abnormalities in cell lines derived from papillary thyroid cancer harboring specific gene alterations.

    Mol. Cytogenet. 4:26-26(2011)

     

    PubMed=22460905; DOI=10.1038/nature11003

    Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

    The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

    Nature 483:603-607(2012)

     

    PubMed=23162534; DOI=10.3389/fendo.2012.00133

    Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A., van Staveren W.C.G., Maenhaut C.

    Thyroid cancer cell lines: an overview.

    Front. Endocrinol. 3:133-133(2012)

     

    PubMed=23833040; DOI=10.1210/jc.2013-2383

    Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.

    Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

    J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

     

    PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

    Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

    A landscape of pharmacogenomic interactions in cancer.

    Cell 166:740-754(2016)

     

    PubMed=28775782; DOI=10.7150/jca.18855

    Caria P., Pillai R., Dettori T., Frau D.V., Zavattari P., Riva G., Romano G., Pani F., Bentivegna A., Giovannoni R., Pagni F., Sogos V., Vanni R.

    Thyrospheres from B-CPAP cell line with BRAF and TERT promoter mutations have different functional and molecular features than parental cells.

    J. Cancer 8:1629-1639(2017)

     

    PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953

    Landa I., Pozdeyev N., Korch C., Marlow L.A., Smallridge R.C., Copland J.A., Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.

    Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.

    Clin. Cancer Res. 25:3141-3151(2019)

     

    PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

    Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

    An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

    Cancer Res. 79:1263-1273(2019)

     

    PubMed=31068700; DOI=10.1038/s41586-019-1186-3

    Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

    Next-generation characterization of the Cancer Cell Line Encyclopedia.

    Nature 569:503-508(2019)

     

    PubMed=31395879; DOI=10.1038/s41467-019-11415-2

    Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

    Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

    Nat. Commun. 10:3574-3574(2019)

    青旗(上海)生物技術(shù)發(fā)展有限公司,總部位于上海浦東新區(qū),依托本地高校資源,逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺,在標(biāo)準(zhǔn)化細(xì)胞庫建立及細(xì)胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營原代細(xì)胞、細(xì)胞系、ELISA試劑盒、感受態(tài)細(xì)胞和HPLC檢測等科研產(chǎn)品與服務(wù)。我們秉承對用戶負(fù)責(zé)的態(tài)度,以對科研的高度嚴(yán)謹(jǐn),以嚴(yán)格的質(zhì)量控制,為廣大生物醫(yī)學(xué)科研用戶提供更優(yōu)質(zhì)的服務(wù)! 



    留言框

    • 產(chǎn)品:

    • 您的單位:

    • 您的姓名:

    • 聯(lián)系電話:

    • 常用郵箱:

    • 省份:

    • 詳細(xì)地址:

    • 補(bǔ)充說明:

    • 驗(yàn)證碼:

      請輸入計(jì)算結(jié)果(填寫阿拉伯?dāng)?shù)字),如:三加四=7

    聯(lián)


    性无码专区无码片| 中文字幕在线免费看线人| 高清无码v视频日本www| 亚洲中文字幕无码专区| 亚洲av日韩av无码黑人| 中文字幕在线播放| 亚洲色中文字幕无码AV| 精品久久久久久无码国产| 无码少妇一区二区三区浪潮AV| 久久久久综合中文字幕| 自拍中文精品无码| 精品人妻少妇嫩草AV无码专区| 无码人妻一区二区三区在线| 成人午夜亚洲精品无码网站| 日韩乱码人妻无码中文字幕视频 | 开心久久婷婷综合中文字幕| 国产成人一区二区三中文| 国产福利电影一区二区三区久久老子无码午夜伦不 | 日本妇人成熟免费中文字幕 | 日韩人妻无码一区二区三区99 | 午夜不卡久久精品无码免费| 日韩精品无码视频一区二区蜜桃 | 精品国产V无码大片在线看| 最好看更新中文字幕| 三级理论中文字幕在线播放| 中文字幕7777| 人妻精品久久久久中文字幕69| 色噜噜亚洲精品中文字幕| 亚洲无码精品浪潮| 中文字幕亚洲欧美日韩2019| 欧美乱人伦中文字幕在线| 中文字字幕在线中文无码| 中文字幕乱码人妻无码久久 | 亚洲中文字幕久久精品无码APP| 亚洲人成无码www久久久| 中文字幕无码av激情不卡久久| 久久亚洲av无码精品浪潮| 亚洲av无码成人精品区在线播放| 亚洲v国产v天堂a无码久久| 中文字幕无码人妻AAA片| 日韩中文字幕在线播放|